Equities research analysts expect that Mallinckrodt PLC (NYSE:MNK) will announce earnings of $2.01 per share for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Mallinckrodt’s earnings, with estimates ranging from $1.90 to $2.09. Mallinckrodt posted earnings of $2.10 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.3%. The firm is scheduled to report its next earnings report before the market opens on Tuesday, November 5th.
On average, analysts expect that Mallinckrodt will report full-year earnings of $8.48 per share for the current year, with EPS estimates ranging from $8.28 to $8.61. For the next year, analysts anticipate that the firm will post earnings of $7.23 per share, with EPS estimates ranging from $5.54 to $8.50. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Mallinckrodt.
Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, August 6th. The company reported $2.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.10 by $0.43. The firm had revenue of $823.30 million during the quarter, compared to analyst estimates of $817.55 million. Mallinckrodt had a negative net margin of 111.46% and a positive return on equity of 18.96%. The business’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 earnings per share.
A number of analysts have recently issued reports on the stock. SunTrust Banks lowered their target price on shares of Mallinckrodt to $7.00 and set a “positive” rating for the company in a research note on Monday, August 12th. Barclays set a $5.00 target price on shares of Mallinckrodt and gave the company a “hold” rating in a research note on Tuesday, September 10th. Stifel Nicolaus lowered their target price on shares of Mallinckrodt from $20.00 to $8.00 and set a “hold” rating for the company in a research note on Monday, September 9th. Cantor Fitzgerald set a $18.00 target price on shares of Mallinckrodt and gave the company a “buy” rating in a research note on Friday, July 12th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Mallinckrodt in a research note on Thursday, September 5th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $10.19.
Shares of MNK opened at $2.54 on Tuesday. The firm has a market capitalization of $223.47 million, a P/E ratio of 0.32, a P/E/G ratio of 0.03 and a beta of 2.48. Mallinckrodt has a 12-month low of $1.43 and a 12-month high of $32.34. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 1.57. The firm has a fifty day moving average price of $2.47 and a 200-day moving average price of $8.79.
Several hedge funds have recently added to or reduced their stakes in MNK. Parallel Advisors LLC raised its holdings in shares of Mallinckrodt by 1,239.3% in the second quarter. Parallel Advisors LLC now owns 3,000 shares of the company’s stock valued at $28,000 after acquiring an additional 2,776 shares in the last quarter. Coastal Capital Group Inc. bought a new stake in shares of Mallinckrodt in the second quarter valued at about $31,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Mallinckrodt by 151.0% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,173 shares of the company’s stock worth $84,000 after purchasing an additional 5,519 shares in the last quarter. Quantamental Technologies LLC bought a new position in Mallinckrodt in the second quarter worth about $84,000. Finally, Teza Capital Management LLC bought a new position in Mallinckrodt in the second quarter worth about $92,000.
Mallinckrodt Company Profile
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.
See Also: Benefits of owning preferred stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.